{
  "docId": "019de071-f579-76ad-bea5-b34da2c83a75",
  "docSlug": "563487226462eb4ab63630eb9b74a5cf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 42,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a split-layout to contrast established late-stage assets (Imfinzi, Enhertu) with early-stage pipeline candidates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/31",
  "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75",
  "deckJsonHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75.json",
  "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "GEJ = gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; CN = China; PT= pan-tumor; TROP2 = trophoblast cell surface antigen 2; HER2-ve = HER2-negative; B7H4 = v-set domain-containing T-cell activation inhibitor 1; ADC = antibody drug conjugate; CD73 = cluster of differentiation 73; mAb = monoclonal antibody; LIF1 = leukaemia inhibitory factor 1.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad4737db-f646-4633-8036-319fb0abdeda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "image",
      "text": "Imfinzi logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a57072d-c790-41a5-a3c6-bf7d54d52a16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.04,
        "y": 0.57
      },
      "kind": "image",
      "text": "Enhertu logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f478bf1d-7dc5-4a77-892f-a72aee351c15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.38,
        "x": 0.25,
        "y": 0.32
      },
      "kind": "list",
      "text": "EMERALD-1: locoregional HCC; data H2 2022; EMERALD-2: adjuvant HCC; data 2022+; MATTERHORN: resectable gastric / GEJ; data 2022+; KUNLUN: locally-advanced oesophageal; data 2022+",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "546e0a78-7e1a-4e5a-9d64-d0d3ffc72c1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.38,
        "x": 0.25,
        "y": 0.57
      },
      "kind": "list",
      "text": "DESTINY-Gastric03: HER2+ gastric / GEJ; data 2022+; DESTINY-Gastric04: 2L gastric / GEJ; data 2022+; DESTINY-Gastric06: 3L HER2+ CN; data 2022+; DESTINY-CRC02: 3L HER2+ CN; data 2022+; DESTINY-PT01: CRC, liver and gastric; data 2022+; DESTINY-PT02: BTC and pancreatic; data 2022+",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "993bbf83-85c6-41c5-a621-46e640b60bf2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.28,
        "x": 0.67,
        "y": 0.32
      },
      "kind": "list",
      "text": "datopotamab deruxtecan (TROP2 ADC) HER2-ve gastric/GEJ and oesophageal; AZD8205 (B7H4 ADC) cholangiocarcinoma; oleclumab (CD73 mAb) pancreatic; AZD0171 (LIF1 mAb) pancreatic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b81f5eca-e8a6-45a7-8090-d29c6a6126ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "AZ poised to become a leader in GI cancers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d1c3c70-17db-4540-949d-c840db9e8fd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.04,
        "y": 0.255
      },
      "kind": "title",
      "text": "Late-stage clinical programmes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cc63e29-4770-4e1a-866c-f070297e399f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.67,
        "y": 0.255
      },
      "kind": "title",
      "text": "Selected early-stage",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99a1964f-90d4-463b-9ca1-f4fe7e769f20",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "0d573158-5c67-408e-872e-e1f79ea9ae0a",
      "evidence": "Although not directly visible, the list of multiple ongoing clinical trials could imply a 2x2 matrix or similar structure for organizing data.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 32,
      "from": 26,
      "beatId": "b07cebc3-7a8b-44be-bf05-017bb65452c0",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck concludes with a discussion of the commercial opportunity and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}